Fractyl Health priced a $60 million offering of 60 million shares at $1.00 each, closing expected September 29, 2025.
Quiver AI Summary
Fractyl Health, Inc. announced the pricing of an underwritten offering of 60 million shares of its common stock at $1.00 per share, aiming to raise approximately $60 million in gross proceeds before expenses. This offering is set to close around September 29, 2025, pending customary conditions. BofA Securities and Evercore ISI are joint book-running managers, with Ladenburg Thalmann as lead manager for the offering. Fractyl, based in Burlington, Massachusetts, focuses on innovative treatments for obesity and type 2 diabetes, striving to shift from symptomatic management to therapies that address the root causes of these metabolic diseases. The offering follows a shelf registration statement filed with the SEC in March 2025, which has been declared effective.
Potential Positives
- Fractyl Health has successfully priced an underwritten offering of 60 million shares of common stock, indicating strong investor interest and confidence in the company's growth potential.
- The gross proceeds of approximately $60 million will provide Fractyl with additional capital to support its operations and further its mission in developing therapeutic solutions for obesity and type 2 diabetes.
- The offering demonstrates Fractyl's robust financial strategy, as it utilizes a previously declared effective shelf registration statement, reflecting well on its regulatory compliance and planning.
- Fractyl's extensive intellectual property portfolio, comprising 33 granted U.S. patents and around 40 pending applications, positions the company favorably in the competitive landscape of metabolic therapeutics.
Potential Negatives
- The underwritten offering of 60 million shares at a price of $1.00 per share may signify a lack of investor confidence, suggesting the company might be undervalued or facing financial difficulties.
- The issuance of a large number of shares can lead to dilution of existing shareholders' equity, potentially impacting the stock price negatively.
- Relying on public offerings to raise funds could indicate a cash flow issue or an inability to secure financing through other means, which may concern investors about the company's financial health.
FAQ
What is the price of Fractyl Health's common stock offering?
The common stock offering is priced at $1.00 per share.
How much money is Fractyl Health raising through this offering?
Fractyl Health aims to raise approximately $60 million from the offering.
When is the expected closing date for the offering?
The offering is expected to close on or about September 29, 2025.
Who are the underwriters for the stock offering?
BofA Securities and Evercore ISI are acting as joint book-running managers, with Ladenburg Thalmann as a lead manager.
Where can I find more information about the stock offering?
More information will be available in the final prospectus filed with the SEC and on their website at www.sec.gov.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GUTS Hedge Fund Activity
We have seen 31 institutional investors add shares of $GUTS stock to their portfolio, and 48 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GENERAL CATALYST GROUP MANAGEMENT, LLC added 4,884,193 shares (+inf%) to their portfolio in Q2 2025, for an estimated $7,912,392
- BLACKROCK, INC. removed 1,569,187 shares (-63.9%) from their portfolio in Q2 2025, for an estimated $2,542,082
- MILLENNIUM MANAGEMENT LLC added 511,825 shares (+4591.2%) to their portfolio in Q2 2025, for an estimated $829,156
- GEODE CAPITAL MANAGEMENT, LLC removed 404,971 shares (-78.6%) from their portfolio in Q2 2025, for an estimated $656,053
- VANGUARD GROUP INC removed 191,096 shares (-14.7%) from their portfolio in Q2 2025, for an estimated $309,575
- NORTHERN TRUST CORP removed 178,659 shares (-92.4%) from their portfolio in Q2 2025, for an estimated $289,427
- ALYESKA INVESTMENT GROUP, L.P. removed 150,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $178,500
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$GUTS Analyst Ratings
Wall Street analysts have issued reports on $GUTS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/15/2025
- Ladenburg Thalmann issued a "Buy" rating on 08/28/2025
- Canaccord Genuity issued a "Buy" rating on 08/14/2025
To track analyst ratings and price targets for $GUTS, check out Quiver Quantitative's $GUTS forecast page.
$GUTS Price Targets
Multiple analysts have issued price targets for $GUTS recently. We have seen 4 analysts offer price targets for $GUTS in the last 6 months, with a median target of $7.5.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $9.0 on 09/15/2025
- Jeff Cohen from Ladenburg Thalmann set a target price of $3.6 on 08/28/2025
- Whitney Ijem from Canaccord Genuity set a target price of $6.0 on 08/14/2025
Full Release
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced the pricing of an underwritten offering of 60 million shares of its common stock at a price of $1.00 per share. All of the securities are being offered by Fractyl. The gross proceeds from the offering to Fractyl are expected to be approximately $60 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about September 29, 2025, subject to customary closing conditions.
BofA Securities and Evercore ISI are acting as joint book-running managers and Ladenburg Thalmann is acting as lead manager for the underwritten offering.
A shelf registration statement relating to the securities offered in the offering described above was filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2025, and declared effective by the SEC on March 18, 2025. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255, Attention: Prospectus Department or by email: [email protected] ; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200 or by email at [email protected] .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. The Company has a robust and growing IP portfolio, with 33 granted U.S. patents and approximately 40 pending U.S. applications, along with numerous foreign issued patents and pending applications. Fractyl is based in Burlington, MA.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the timing, size, terms and completion of the Company’s underwritten offering. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Fractyl’s business are described in detail in its SEC filings, including in Fractyl’s Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Fractyl makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Fractyl disclaims any obligation to update these statements except as may be required by law.
Contacts
Media Contact
Jessica Cotrone, Head of Corporate Communications
[email protected], 978.760.5622
Investor Contact
Brian Luque, Head of Investor Relations and Corporate Development
[email protected], 951.206.1200
BURLINGTON, Mass., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced the pricing of an underwritten offering of 60 million shares of its common stock at a price of $1.00 per share. All of the securities are being offered by Fractyl. The gross proceeds from the offering to Fractyl are expected to be approximately $60 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about September 29, 2025, subject to customary closing conditions.
BofA Securities and Evercore ISI are acting as joint book-running managers and Ladenburg Thalmann is acting as lead manager for the underwritten offering.
A shelf registration statement relating to the securities offered in the offering described above was filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2025, and declared effective by the SEC on March 18, 2025. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255, Attention: Prospectus Department or by email: [email protected] ; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200 or by email at [email protected] .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. The Company has a robust and growing IP portfolio, with 33 granted U.S. patents and approximately 40 pending U.S. applications, along with numerous foreign issued patents and pending applications. Fractyl is based in Burlington, MA.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the timing, size, terms and completion of the Company’s underwritten offering. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Fractyl’s business are described in detail in its SEC filings, including in Fractyl’s Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Fractyl makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Fractyl disclaims any obligation to update these statements except as may be required by law.
Contacts
Media Contact
Jessica Cotrone, Head of Corporate Communications
[email protected], 978.760.5622
Investor Contact
Brian Luque, Head of Investor Relations and Corporate Development
[email protected], 951.206.1200
